Gilead begins clinical study of inhaled remdesivir for COVID-19 treatment

Gilead Sciences yesterday said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement, Gilead said the inhaled version could better target respiratory infections and limit systemic exposure to remdesivir and be accessible to non-hospitalized patients. In the placebo-controlled trial, Gilead said it will enroll approximately 60 healthy U.S. adults to evaluate the drug’s safety, tolerability and pharmacokinetics.